A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
National Cancer Center Hospital East
Seagen Inc.
Astellas Pharma Inc
Servier
Sotio Biotech Inc.
Rondo Therapeutics
Washington University School of Medicine
Daiichi Sankyo
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sutro Biopharma, Inc.
Neonc Technologies, Inc.
Merck Sharp & Dohme LLC
Shanghai Henlius Biotech
Seagen Inc.
Qurient Co., Ltd.
AstraZeneca
Seagen Inc.
Tizona Therapeutics, Inc
Essen Biotech
Nouscom SRL
H. Lee Moffitt Cancer Center and Research Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Takeda
RemeGen Co., Ltd.
Rutgers, The State University of New Jersey
ImmunityBio, Inc.
Amgen
Linnaeus Therapeutics, Inc.
Inhibrx Biosciences, Inc
Suzhou Transcenta Therapeutics Co., Ltd.
Merck Sharp & Dohme LLC
University of Pittsburgh
Cedars-Sinai Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Hanmi Pharmaceutical Company Limited
Sanofi
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
Hoosier Cancer Research Network
NuCana plc
University of Colorado, Denver
Medicenna Therapeutics, Inc.
Mayo Clinic
OncoC4, Inc.
Aprea Therapeutics
Imugene Limited